New antibody drug takes aim at Hard-to-Treat cancers

NCT ID NCT07337525

Recruiting now Disease control Sponsor: Pilatus Biosciences Inc Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This early-stage trial is testing a new drug called PLT012 in adults with advanced solid tumors that have not responded to standard treatments. PLT012 is an antibody that targets a protein called CD36 found on some cancer cells. The main goals are to find safe doses and to see if the drug can shrink tumors or slow cancer growth. All 36 participants will receive PLT012 by IV every three weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PLT012 (an antibody that targets CD36, a protein on some cancer cells)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, not proof of effectiveness. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer cholangiocarcinoma digestive system neoplasm Liver Neoplasms neoplasm Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANT SOLID TUMOR SOLID TUMOR CANCER

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
NEXT Dallas
RECRUITING

Dallas, Texas, 75039, United States
NEXT Houston
RECRUITING

Houston, Texas, 77054, United States
USC Norris Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.